BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
NEW YORK and PETACH TIKVAH, Israel, May 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report first quarter 2015 financial results on Thursday, May 14, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. Eastern Time to discuss the results.
Conference Call & Webcast
Thursday, May 14, 2015 at 8:30 a.m. ET/5:30 a.m. PT
Domestic: 888-299-7209
International: 719-325-2244
Conference ID: 9028301
Webcast: http://public.viavid.com/player/index.php?id=114583
Replay
Available through May 28, 2015
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 9028301
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Logo - http://photos.prnewswire.com/prnh/20141006/150511
SOURCE BrainStorm Cell Therapeutics Inc.
Share this article